1801 Stock Overview
A biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Innovent Biologics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$38.50 |
| 52 Week High | HK$52.15 |
| 52 Week Low | HK$28.30 |
| Beta | 0.25 |
| 11 Month Change | -15.75% |
| 3 Month Change | -11.39% |
| 1 Year Change | -12.50% |
| 33 Year Change | -48.46% |
| 5 Year Change | 35.56% |
| Change since IPO | 132.21% |
Recent News & Updates
Recent updates
Shareholders May Not Be So Generous With Innovent Biologics, Inc.'s (HKG:1801) CEO Compensation And Here's Why
Jun 14
Innovent Biologics, Inc. (HKG:1801) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
May 01There's Reason For Concern Over Innovent Biologics, Inc.'s (HKG:1801) Massive 27% Price Jump
Feb 28Are Investors Undervaluing Innovent Biologics, Inc. (HKG:1801) By 33%?
Jan 12Innovent Biologics, Inc.'s (HKG:1801) Price Is Out Of Tune With Revenues
Dec 25An Intrinsic Calculation For Innovent Biologics, Inc. (HKG:1801) Suggests It's 34% Undervalued
Sep 11Is There An Opportunity With Innovent Biologics, Inc.'s (HKG:1801) 50% Undervaluation?
Jun 04Benign Growth For Innovent Biologics, Inc. (HKG:1801) Underpins Its Share Price
May 14Innovent Biologics, Inc. (HKG:1801) Shares Could Be 50% Below Their Intrinsic Value Estimate
Dec 27Shareholder Returns
| 1801 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 2.1% | 1.5% | 0.4% |
| 1Y | -12.5% | -11.2% | 12.0% |
Return vs Industry: 1801 underperformed the Hong Kong Biotechs industry which returned -11.2% over the past year.
Return vs Market: 1801 underperformed the Hong Kong Market which returned 12% over the past year.
Price Volatility
| 1801 volatility | |
|---|---|
| 1801 Average Weekly Movement | 8.6% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 18.9% |
| 10% least volatile stocks in HK Market | 4.3% |
Stable Share Price: 1801 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1801's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 5,263 | Michael Yu | www.innoventbio.com |
Innovent Biologics, Inc., a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People’s Republic of China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor. The company is also developing IBI-326, a fully-human BCMA CAR T-cell therapy; IBI-376, an oral inhibitor of PI3Kd; IBI-351, a KRASG12C inhibitor; IBI-344, a repressor of silencing 1/TRK tyrosine kinase inhibitor; IBI-126, an ADC targeting CEACAM5; IBI-306, a novel anti-proprotein convertase subtilisin/kexin type 9 enzyme monoclonal antibody; IBI-362, a glucagon-like peptide-1 receptor/glucagon receptor dual agonist; and IBI-112, a novel long-acting anti-IL-23.
Innovent Biologics, Inc. Fundamentals Summary
| 1801 fundamental statistics | |
|---|---|
| Market cap | HK$63.55b |
| Earnings (TTM) | -HK$1.38b |
| Revenue (TTM) | HK$8.01b |
7.9x
P/S Ratio-45.8x
P/E RatioIs 1801 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1801 income statement (TTM) | |
|---|---|
| Revenue | CN¥7.46b |
| Cost of Revenue | CN¥2.12b |
| Gross Profit | CN¥5.34b |
| Other Expenses | CN¥6.62b |
| Earnings | -CN¥1.28b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.78 |
| Gross Margin | 71.58% |
| Net Profit Margin | -17.18% |
| Debt/Equity Ratio | 25.8% |
How did 1801 perform over the long term?
See historical performance and comparison